Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
- Sysco calls on Teamsters to end LA strike after economic deal reached
Edwards Lifesciences (EW) PT Raised to $260 at RBC Capital
October 24, 2019 6:25 AM EDTRBC Capital analyst Brandon Henry raised the price target on Edwards Lifesciences (NYSE: EW) to $260.00 (from $250.00) while maintaining an Outperform rating.
US TAVR growth of +30%"We now model 2019 and 2020 revenues of $4.32B (previously $4.22B) and $4.74B (previously $4.64B), respectively. Moving to the... MoreEdwards Lifesciences (EW) Tops Q3 EPS by 19c, Updates FY Guidance
October 23, 2019 4:20 PM EDTEdwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.41, $0.19 better than the analyst estimate of $1.22. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.
GUIDANCE:
Edwards Lifesciences sees FY2019 EPS of $5.50-$5.65, versus the consensus of $5.34.... More



